Feb. 04, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical technology company focused on the design, development, and commercialization of novel technologies for people with ...

In a stark reflection of the challenges facing the tech sector, GCTK's stock has tumbled to a 52-week low, touching down at a mere $0.06, with a market capitalization shrinking to just $0.99 million.

Glucotrack (GCTK) will participate in the FORGETDIABETES bionic pancreas initiative that will develop a long-term, automated insulin delivery ...

(Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that ...

GlucoTrack (NASDAQ:GCTK) just reported results for the first quarter of 2024. GlucoTrack reported earnings per share of -12 cents. The company did not report any revenue for the quarter.

This data feed is not available at this time. Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.

(RTTNews) - Glucotrack, Inc. (GCTK), Wednesday, announced the results from its first-in-human trial of its continuous blood glucose monitoring or CBGM system, which will be presented at the 2025 ...

About Glucotrack, Inc. Glucotrack, Inc. (NASDAQ: GCTK) is focused on the design, development, and commercialization of novel technologies for people with diabetes. The Company is currently ...

Next Generation AI-Driven Analytics to Unlock Key Insights from the Ongoing Continuous Blood Glucose Monitoring Clinical Study DataRUTHERFORD, N.J. and STOCKHOLM, April 03, 2025 (GLOBE NEWSWIRE) -- ...